The reversible effects of raloxifene on luteinizing hormone levels and ovarian morphology in mice

Reproductive Toxicology

Volumn 14, Issue 1, 2000, Pages 37-44

  Cohen, Ilene R ^a   Sims, Millie L ^a   Robbins, Michelle R ^a   Lakshmanan, Mark C ^a   Francis, Paul C ^a   Long, Gerald G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Luteinizing hormone; Mouse; Ovary; Raloxifene; SERMs

Indexed keywords

ESTROGEN RECEPTOR; LUTEINIZING HORMONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; CORPUS LUTEUM; CORPUS LUTEUM FUNCTION; DIETARY INTAKE; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; FEMALE; GROWTH, DEVELOPMENT AND AGING; HISTOPATHOLOGY; IATROGENIC DISEASE; LUTEINIZING HORMONE RELEASE; MOUSE; NONHUMAN; OVARY; OVARY DEVELOPMENT; OVARY FOLLICLE; OVARY FOLLICLE MATURATION; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY;

ANIMALIA;

EID: 0034013894     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(99)00065-9     Document Type: Article

References (40)

1. Mitlak B.H., Cohen F.J. In search of optimal long-term female hormone replacement the potential of selective estrogen receptor modulators . Horm Res. 48:1997;155-163.
2. Baker V.L., Jaffe R.B. Clinical uses of antiestrogens. Obstet Gynecol Surv. 51:1996;45-59.
3. Maenpaa J.U., Ala-Fossi S.L. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost. Drugs Aging. 11:1997;261-270.
4. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P.J., Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 81:1993;660-664.
5. Sato M., Rippy M.K., Bryant H.U. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats. FASEB J. 10:1996;905-912.
6. Black L.J., Sato M., Rowley E.R., et al. Raloxifene (LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest. 93:1994;63-69.
7. Delmas P.D., Bjarnason N.H., Mitlak B.H., et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 337:1997;1641-1647.
8. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D., Arnaud C. A controlled trial of raloxifene (LY139481) HCl impact on bone turnover and serum lipid profile in healthy postmenopausal women . J Bone Miner Res. 11:1996;835-842.
9. Boss S.M., Huster W.J., Neild J.A., Glant M.D., Eisenhut C.C., Draper M. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 177:1997;1458-1464.
10. Tucker M.J., Adam H.K., Patterson J.S. Tamoxifen. Laurence D.R., McLean A.E.M., Weatherall M. Safety Testing of New Drugs. 1984;125-161 Academic Press, London.
11. Fareston Package Insert. Kenilworth, NJ: Schering Corp, 1997.
12. Evista Package Insert. Indianapolis, IN: Eli Lilly, 1997.
13. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 . J Natl Cancer Inst. 86:1994;527-537.
14. Cook L.S., Weiss N.S., Schwartz S.M., et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst. 87:1995;1359-1364.
15. Curtis R.E., Boice J.D.J., Shriner D.A., Hankey B.F., Fraumeni J.F.J. Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst. 88:1996;832-834.
16. Brambell F.W.R., Parkes A.S., Fielding U. Changes in the ovary of the mouse following exposure to x-rays. Proc R Soc Lond B Biol Sci. 101:1937;29-60.
17. Biskind M.S., Biskind G.S. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med. 55:1944;176-179.
18. Marchant J. The chemical induction of ovarian tumours in mice. Br J Cancer. 11:1957;452-464.
19. Murphy E.D., Beamer W.G. Plasma gonadotropin levels during early stages of ovarian tumorigenesis in mice of the Wx-Wu genotype. Cancer Res. 33:1973;721-723.
20. Lubahn D.B., Moyer J.S., Golding T.S., Couse J.F., Korach K.S., Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA. 90:1993;11162-11166.
21. Risma K.A., Hirshfield A.N., Nilson J.H. Elevated luteinizing hormone in prepubertal transgenic mice causes hyperandrogenemia, precocious puberty, and substantial ovarian pathology. Endocrinology. 138:1997;3540-3547.
22. Matzuk M.M., Finegold M.J., Su J.G., Hsueh A.J., Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature. 360:1992;313-319.
23. Niswender G.D., Chen C.L., Midgley A.R.J., Meites J., Ellis S. Radioimmunoassay for rat prolactin. Proc Soc Exp Biol Med. 130:1969;793-797.
24. JMP Statistical Package. Cary, NC: SAS Institute, 1995.
25. Parkening T.A., Collins T.J., Smith E.R. Plasma and pituitary concentrations of LH, FSH and prolactin in aged female C57BL/6 mice. J Reprod Fertil. 58:1980;377-386.
26. Gee D.M., Flurkey K., Finch C.E. Aging and the regulation of luteinizing hormone in C57BL/6J mice impaired elevations after ovariectomy and spontaneous elevations at advanced ages . Biol Reprod. 28:1983;598-607.
27. Yang N.N., Venugopalan M., Hardikar S., Glasebrook A. Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science. 273:1996;1222-1225.
28. Korach K.S. Insights from the study of animals lacking functional estrogen receptor. Science. 266:1994;1524-1527.
29. Scully K.M., Gleiberman A.S., Lindzey J., Lubahn D.B., Korach K.S., Rosenfeld M.G. Role of estrogen receptor-α in the anterior pituitary gland. Mol Endocrinol. 11:1997;674-681.
30. Couse J.F., Curtis S.W., Washburn T.F., et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Mol Endocrinol. 9:1995;1441-1454.
31. Risma K.A., Clay C.M., Nett T.M., Wagner T., Yun J., Nilson J.H. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci USA. 92:1995;1322-1326.
32. Tennent B.J., Beamer W.G. Ovarian tumors not induced by irradiation and gonadotropins in hypogonadal (hpg) mice. Biol Reprod. 34:1986;751-760.
33. Kumar T.R., Wang Y., Matzuk M.M. Gonadotropins are essential modifier factors for gonadal tumor development in inhibin-deficient mice. Endocrinology. 137:1996;4210-4216.
34. Davis B.J., Maronpot R.R. Chemically associated toxicity and carcinogenicity of the ovary. Prog Clin Biol Res. 394:1996;285-308.
35. Capen C.C., Beamer W.G., Tennent B.J., Stitzel K.A. Mechanisms of hormone-mediated carcinogenesis of the ovary in mice. Mutat Res. 333:1995;143-151.
36. Alison R.H., Capen C.C., Prentice D.E. Neoplastic lesions of questionable significance to humans. Toxicol Pathol. 22:1994;179-186.
37. Helzlsouer K.J., Alberg A.J., Gordon G.B., et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer. J Am Med Assoc. 274:1995;1926-1930.
38. Blaakaer J., Djursing H., Hording U., et al. The pituitary-gonadal axis in women with benign or malignant ovarian tumors. Acta Endocrinol (Copenhagen). 127:1992;127-130.
39. Weiss N.S., Hill D.A. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas. 23:1996;235-239.
40. Cramer D.W., Barbieri R.L., Muto M.G., Kelly A., Brucks J.P., Harlow B.L. Characteristics of women with a family history of ovarian cancer. II. Follicular phase hormone levels. Cancer. 74:1994;1318-1322.